Lipid-lowering effect was observed during treatment with tenofovirdisoproxil fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic fea-tures in patients switching from TDF to tenofovir alafenamide (TAF) remain unclear. To compare the impacts of switching from TDF to TAF or from entecavir to TAFon body weight and metabolic features in patients with CHB.

This was a multi-centre, prospective, observational study in patients withCHB on TDF or entecavir who switched to TAF. Baseline characteristics, lipid pro-file and sugar profile were determined. This study received IRB approval from eachhospital.

We enrolled 177 patients on TDF (99) or entecavir (78) and followed themfor 48 weeks after the switch to TAF. At baseline, TDF-experienced patients hadlower serum triglyceride, total cholesterol, high-density lipoprotein (HDL) cholesteroland low-density lipoprotein (LDL) cholesterol than entecavir-experienced patients.The switch from TDF to TAF significantly increased body weight, triglyceride, totalcholesterol, HDL, LDL, fasting glucose, glycaemic haemoglobin, insulin and insulinresistance. The switch from entecavir to TAF did not affect these measures. Therewas no significant difference in atherosclerotic cardiovascular disease risk scores be-tween groups.(Link)

Reference: Cheng, P. N., Feng, I. C., Chen, J. J., Kuo, H. T., Lee, P. L., Yu, M. L., ... & Liu, C. J. (2024). Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 59(2), 230-238.